Drug intelligence / Profile preview

Cangpo Liujun Prescription

Development stage: Phase 2
Lead developer: Hangzhou First People's Hospital
Administration: Oral

Overview

Cangpo Liujun Prescription is a traditional Chinese medicine (TCM) formulation developed by the First People's Hospital of Hangzhou for the treatment of cancer-related fatigue (CRF). It is specifically indicated for patients with advanced colorectal cancer undergoing second-line chemotherapy who exhibit the TCM syndrome of spleen deficiency and dampness excess. As a botanical mixture, it is typically administered as an oral decoction. The prescription is currently being investigated in a Phase 2 clinical trial (NCT06394128) to evaluate its efficacy in improving fatigue symptoms and its potential role in modulating the intestinal microbiota and immune function.

Other names: Cangpo Liujun decoction

Beyond the preview

Go deeper on Cangpo Liujun Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cangpo Liujun Prescription.

Explore the full profile